Alessandro D Santin Selected Research

1-oleoyl-2-stearoylphosphatidylcholine

3/2007	Gene expression profile of ovarian serous papillary carcinomas: identification of metastasis-associated genes.
11/2006	Differential gene expression profiles between tumor biopsies and short-term primary cultures of ovarian serous carcinomas: identification of novel molecular biomarkers for early diagnosis and therapy.
10/2004	Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: identification of candidate molecular markers for ovarian cancer diagnosis and therapy.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Alessandro D Santin Research Topics

Disease

150	Neoplasms (Cancer) 05/2024 - 02/2002
74	Carcinoma (Carcinomatosis) 12/2023 - 11/2003
49	Ovarian Neoplasms (Ovarian Cancer) 02/2024 - 02/2002
44	Endometrial Neoplasms (Endometrial Cancer) 01/2023 - 08/2004
31	Uterine Cervical Neoplasms (Cancer of the Cervix) 02/2024 - 12/2002
18	Ovarian Epithelial Carcinoma 09/2023 - 02/2007
17	Carcinosarcoma 05/2024 - 06/2007
16	Papillary Carcinoma 01/2019 - 10/2004
7	Neoplasm Metastasis (Metastasis) 02/2022 - 11/2003
7	Disease Progression 10/2021 - 08/2008
6	Ascites 02/2022 - 06/2004
6	Adenocarcinoma 01/2020 - 09/2008
5	Infections 12/2023 - 07/2009
5	Ovarian Diseases (Ovarian Disease) 12/2015 - 07/2009
5	Endometrioid Carcinoma 12/2011 - 05/2005
3	COVID-19 12/2023 - 06/2021
3	Turcot syndrome 01/2023 - 01/2022
3	Breast Neoplasms (Breast Cancer) 02/2022 - 06/2003
3	Squamous Cell Carcinoma (Epidermoid Carcinoma) 11/2019 - 06/2011
3	Uterine Neoplasms (Uterine Cancer) 01/2018 - 06/2004
2	Post-Acute COVID-19 Syndrome 02/2024 - 12/2023
2	Inflammation (Inflammations) 02/2024 - 12/2023

Drug/Important Bio-Agent (IBA)

33	Proteins (Proteins, Gene)FDA Link 07/2023 - 01/2005
20	Immunoconjugates (Immunoconjugate)IBA 12/2023 - 10/2014
19	Trastuzumab (Herceptin)FDA Link 12/2022 - 05/2002
17	PlatinumIBA 03/2024 - 08/2007
16	Paclitaxel (Taxol)FDA LinkGeneric 01/2023 - 08/2004
15	Biomarkers (Surrogate Marker)IBA 02/2024 - 05/2005
12	ParaffinIBA 01/2020 - 11/2003
12	Claudin-3IBA 01/2019 - 10/2004
11	pembrolizumabIBA 11/2023 - 01/2018
11	Monoclonal AntibodiesIBA 10/2018 - 02/2004
10	AntigensIBA 01/2021 - 02/2002
9	Immune Checkpoint InhibitorsIBA 01/2023 - 01/2016
9	Clostridium enterotoxinIBA 01/2017 - 05/2005
9	Messenger RNA (mRNA)IBA 07/2013 - 06/2007
8	EnzymesIBA 12/2023 - 01/2004
8	Carboplatin (JM8)FDA LinkGeneric 01/2023 - 08/2004
8	sacituzumab govitecanIBA 01/2021 - 08/2018
8	Claudin-4IBA 01/2019 - 10/2004
8	Epithelial Cell Adhesion MoleculeIBA 01/2016 - 10/2004
7	Epidermal Growth Factor (EGF)IBA 11/2023 - 08/2004
7	neratinibIBA 01/2023 - 10/2014
7	Peptides (Polypeptides)IBA 12/2015 - 05/2005
6	VaccinesIBA 04/2024 - 01/2005
6	TubulinIBA 02/2022 - 04/2012
6	EpitopesIBA 11/2021 - 05/2005
6	Formaldehyde (Formol)FDA Link 01/2020 - 10/2004
6	Interleukin-2 (IL2)IBA 12/2011 - 08/2003
6	Serine Proteases (Serine Protease)IBA 02/2009 - 11/2003
5	Bevacizumab (Avastin)FDA Link 03/2024 - 06/2015
5	ixabepilone (BMS 247550)FDA Link 03/2024 - 07/2013
5	taxaneIBA 01/2022 - 07/2013
5	Tyrosine Kinase InhibitorsIBA 10/2020 - 04/2013
5	CytokinesIBA 01/2016 - 06/2003
5	epothilone B (EPO906)IBA 01/2014 - 10/2010
5	Oncogene Proteins (Oncogene Protein)IBA 07/2009 - 05/2003
4	DNA (Deoxyribonucleic Acid)IBA 04/2024 - 02/2013
4	copanlisibIBA 04/2024 - 11/2019
4	lenvatinibIBA 08/2023 - 01/2022
4	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2023 - 08/2004
4	olaparibIBA 01/2023 - 10/2019
4	RNA (Ribonucleic Acid)IBA 01/2023 - 11/2006
4	MesothelinIBA 01/2023 - 01/2020
4	trastuzumab duocarmazineIBA 01/2021 - 01/2016
4	Ado-Trastuzumab EmtansineIBA 01/2021 - 01/2017
4	OligonucleotidesIBA 03/2007 - 10/2004
4	Kallikreins (Kallikrein)IBA 05/2006 - 08/2004
4	Peptide Hydrolases (Proteases)FDA Link 10/2004 - 11/2003
3	AfatinibIBA 04/2024 - 01/2019
3	trastuzumab deruxtecanIBA 12/2023 - 01/2023
3	Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA 01/2023 - 10/2019
3	Phosphotransferases (Kinase)IBA 01/2023 - 03/2012
3	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2023 - 03/2007
3	Surface Antigens (Surface Antigen)IBA 01/2020 - 01/2020
3	Membrane Glycoproteins (Membrane Glycoprotein)IBA 01/2020 - 12/2010
3	Irinotecan (Camptosar)FDA LinkGeneric 01/2020 - 01/2019
3	Aromatase InhibitorsIBA 01/2019 - 08/2007
3	DuocarmycinsIBA 10/2017 - 01/2016
3	DNA-Directed DNA Polymerase (Polymerases, DNA)IBA 01/2017 - 04/2015
3	IntegrinsIBA 11/2016 - 03/2007
3	ChromiumIBA 01/2016 - 06/2006
3	SolitomabIBA 01/2016 - 02/2015
3	Epothilones (Epothilone)IBA 07/2013 - 01/2013
3	Mammaglobin BIBA 07/2013 - 06/2007
3	Complement System Proteins (Complement)IBA 05/2012 - 09/2007
3	adecatumumabIBA 12/2010 - 01/2010
3	ImmunosorbentsIBA 07/2009 - 07/2005
3	1-oleoyl-2-stearoylphosphatidylcholineIBA 03/2007 - 10/2004
2	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 05/2024 - 02/2024
2	CalciumIBA 12/2023 - 10/2004
2	Topoisomerase I InhibitorsIBA 12/2023 - 01/2023

Therapy/Procedure

71	Drug Therapy (Chemotherapy) 09/2023 - 05/2002
67	Therapeutics 04/2024 - 05/2002
29	Immunotherapy 01/2023 - 02/2002
8	Radiotherapy 01/2021 - 12/2002
4	Salvage Therapy 01/2018 - 06/2003
3	Cytoreduction Surgical Procedures 09/2023 - 02/2013
3	Neoadjuvant Therapy 09/2023 - 02/2013
3	Precision Medicine 01/2017 - 05/2013